Apoptosis and autoimmune disease

Inflammation Research

Volumn 48, Issue 1, 1999, Pages 5-21

  O'Reilly, L A ^a   Strasser, A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Apoptosis; Autoimmunity; Bcl 2; Cell death; Fas (Apo 1, CD95)

Indexed keywords

CELL RECEPTOR; CYSTEINE PROTEINASE; FAS ANTIGEN; LIGAND; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CAENORHABDITIS ELEGANS; CANCER; CELL DEATH; DEGENERATIVE DISEASE; DROSOPHILA MELANOGASTER; ENZYME ACTIVATION; EVOLUTION; GENETIC REGULATION; HASHIMOTO DISEASE; HOMEOSTASIS; HUMAN; INSECT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHADENOPATHY; LYMPHOCYTE; MAMMAL; NEMATODE; NONHUMAN; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR CELL; VIRUS INFECTION;

EID: 0033007598     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050369     Document Type: Review

References (278)

1. [1] Vogt C. Untersuchungen über die Entwicklungsgeschichte der Geburtshelferkröte (Alytes obstertricians). In: Gassman, J.U. Solothum, 1842:130.
2. [2] Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
3. [3] Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991;7:663-98.
4. [4] Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci 1996;93:2239-44.
5. [5] Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997;88:347-54.
6. [6] Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
7. [7] Savill J. Phagocytic docking without shocking. Nature 1998;392:442-3.
8. [8] Kumar S, Lavin MF. The ICE family of cysteine proteases as effectors of cell death. Cell Death and Differentiation 1996; 3:255-67.
9. [9] Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299-306.
10. [10] Raff MC. Size control: the regulation of cell numbers in animal development. Cell 1996;86:173-5.
11. [11] Barr PJ, Tomei LD. Apoptosis and its role in' human disease. Biotechnology 1994;12:487-93.
12. [12] Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
13. [13] Strasser A, Huang DCS, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1997;1333:F151-F78.
14. [14] Korsmeyer SJ. Regulators of cell death. Trends Genet 1995;11:101-5.
15. [15] Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-2.
16. [16] Cory S. Regulation of lymphocyte survival by the BCL-2 gene family. Annu Rev Immunol 1995;13:513-43.
17. [17] Strasser A, O'Connor L, Huang DCS, O'Reilly LA, Stanley ML, Bath ML, et al. Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Behring Inst Mitt 1996;97:101-17.
18. [18] Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996;88:386-401.
19. [19] Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997;20:245-67.
20. [20] Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-88.
21. [21] Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991;67:889-99.
22. [22] Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
23. [23] Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
24. [24] Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
25. [25] Strasser A. Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Curr Opin Immunol 1995;7:228-34.
26. [26] Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997;3:614-20.
27. [27] Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;387:773-6.
28. [28] O'Connor L, Strasser A. In: Kumars, editor. Apoptosis: Biology, Mechanisms and Role in Disease. Springer Verlag, 1998.
29. [29] Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
30. [30] Gibson L, Holmgreen S, Huang DCS, Bernard O, Copeland NG, Jenkins NA, et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 1996;13:665-75.
31. [31] Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993;151:1979-88.
32. [32] Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, el al. A member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994;54:6348-52.
33. [33] Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992;356:494-9.
34. [34] White E, Sabbatini P, Debbas M, Wold WSM, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor α. Mol Cell Biol 1992;12:2570-80.
35. [35] Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein virus-coded BHRF 1 protein, a viral homologue of Bcl-2 protects human B cells from programmed cell death. PNAS 1993;90:8479-83.
36. [36] Afonso CL, Neilan JG, Kutish GF, Rock DL. An African swine fever virus Bcl-2 homolog, 5-HL, suppresses apoptotic cell death. J Virol 1996;70:4858-63.
37. [37] Cheng EHY, Nicholas J, Bellows DS, Hayward GS, Guo HG, Reitz MS, et al. A Bcl-2 homolog encoded by kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with bax or bak. PNAS 1997;94:690-4.
38. [38] Nava VE, Cheng EH-Y, Veliuona M, Zou S, Clem RJ, Mayer ML. Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogcne. J Virol 1997;71:4118-22.
39. [39] Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue. Nature Med 1997;3:293-8.
40. [40] Yin X-M, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
41. [41] Borner C, Martinou I, Mattmann C, Irmler M, Schaerer E, Martinou J-C, et al. The protein bcl-2α does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol 1994;126:1059-68.
42. [42] Huang DCS, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998;17:1029-39.
43. [43] Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-x(L) and Bcl-2 repress a common pathway of cell death. J Exp Med 1995;182:821-8.
44. L displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 1995;182:1973-83.
45. L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 1997;14:405-14.
46. [46] Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
47. [47] Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995;374:733-6.
48. [48] Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995;374:736-9.
49. [49] Farrow SN, White JHM, Martinou I, Raven T, Pun K-T, Grinham CJ, et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995;374:731-3.
50. [50] Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJW. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. PNAS 1997;94:12401-6.
51. L. J Biol Chem 1998;273:8705-10.
52. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
53. [53] Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995;11:1921-8.
54. [54] Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol 1996;16:5857-64.
55. [55] Wang K, Yin X-M, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Gene Dev 1996;10:2859-69.
56. L. EMBO J 1997;16:1686-94.
57. [57] Imaizumi K, Tsuda M, Imai Y, Wanaka A, Takagi T, Tobyama M. Molecular cloning of a novel polypeptide, DP5, induced during programmed neuronal death. J Biol Chem 1997;272:18842-8.
58. [58] Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J Biol Chem 1998;273:7783-6.
59. [59] O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384.
60. [60] Conradt B, Horvitz HR. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell 1998;93:519-95.
61. [61] Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994;79:189-29.
62. L. Nature 1996;379:554-92.
63. [63] Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
64. [64] Xue D, Shaham S, Horvitz HR. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Gene Dev 1996;10:1073-83.
65. [65] Kuida K, Zheng TS, Na S, Kuan C-Y, Yang D, Karasuyama H, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996;384:368-72.
66. [66] Woo M, Hakem R, Soengas MS, Duncan GS, Shahinian A, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Gene Dev 1998;12:806-19.
67. [67] Bump NJ, Hackett M, Hugunin M, Seshagiri S, Brady K, Chen P, et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995;269:1885-8.
68. [68] Sugimoto A, Friesen PD, Rothman JH. Baculovirus p35 prevents developmentally programmed cell death and rescues a ced-9 mutant in the nematode Caenorhabditis elegans. EMBO J 1994;13:2023-8.
69. [69] Hay BA, Wolff T, Rubin CM. Expression of baculovirus P35 prevents cell death in Drosophila. Development 1994;120:2121-9.
70. [70] Beidler DR, Tewari M, Friesen PD, Poirier G, Dixit VM. The baculovirus p35 protein inhibits Fas-and tumor necrosis factor-induced apoptosis. J Biol Chem 1995;270:16526-8.
71. [71] Datta R, Kojima H, Banach D, Bump NJ, Talanian RV, Alnemri ES, et al. Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem 1997;272:1965-9.
72. [72] Walker NP, Talanian RV, Brady KD, Dang LC, Bump NJ, Ferenz CR, et al. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: a (p20/p10)2 homodimer. Cell 1994;78:343-52.
73. [73] Wilson KP, Black J-AF, Thomson JA, Kim EE, Griffith JP, Navia MA, et al. Structure and mechanism of interleukin-1β converting enzyme. Nature 1994;370:270-5.
74. [74] Rotonda J, Nicholson DW, Fazil KM, Gallant M, Gareau Y, Labelle M, et al. The three-dimensional structure of apopain/ cpp32, a key mediator of apoptosis. Nature Struct Biol 1996;3:619-25.
75. [75] Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998;273:2926-30.
76. [76] Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/ MACHα1) death signal. J Biol Chem 1998;273:4345-9.
77. [77] Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998;1:949-57.
78. [78] Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 1997;276:1571-4.
79. [79] Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89:175-84.
80. [80] Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
81. [81] Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96-9.
82. [82] Hengartner MO, Horvitz HR. Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 1994;4:581-6.
83. [83] Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 1997;275:1122-6.
84. [84] Chinnaiyan AM, Chaudhary D, O'Rourke K, Koonin EV, Dixit VM. Role of CED-4 in the activation of CED-3. Nature 1997;388:728-9.
85. [85] Irmler M, Hofmann K, Vaux DL, Tschopp J. Direct physical interaction between the Caenorhabditis elegans death proteins ced-3 and ced-4. FEBS Lett 1997;406:189-90.
86. [86] Seshagiri S, Miller LK. Caenorhabditis Elegans Ced-4 Stimulates Ced-3 Processing and Ced-3-Induced Apoptosis. Curr Biol 1997;7:455-60.
87. [87] Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 1997;385:653-6.
88. [88] Wu DY, Wallen HD, Nunez G. Interaction and Regulation Of Subcellular Localization Of Ced-4 By Ced-9. Science 1997;275:1126-9.
89. [89] Shaham S, Horvitz HR. Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. Gene Dev 1996;10:578-91.
90. [90] Wu D, Wallen HD, Nuñez G. Interaction and regulation of subcellular localization of CED-4 by CED-9. Science 1997;275:1126-9.
91. [91] Estoppey S, Rodriguez I, Sadoul R, Martinou J-C. Bcl-2 prevents activation of CPP32 cysteine protease and cleavage of poly (ADP-ribose) polymerase and U1-70 kD proteins in staurosporine-mediated apoptosis. Cell Death Differ 1997;4:34-8.
92. [92] Perry DK, Smyth MJ, Wang H-G, Reed JC, Duriez P, Poirier GG, et al. Bcl-2 acts upstream of the PARP protease and prevents its activation. Cell Death Differ 1997;4:29.
93. L, and Apaf-1 form a ternary complex. J Biol Chem 1998;273:5841-33.
94. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. PNAS 1998;95:4386-91.
95. L. Cell 1996;87:619-28.
96. [96] von Freeden-Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 1997;7:147-54.
97. [97] del Peso L, González-Garcia M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-9.
98. [98] Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
99. L, an inhibitor of programmed cell death. Nature 1996;381:335-41.
100. L forms an ion channel in synthetic lipid membranes. Nature 1997;385:353-7.
101. [101] Schendel SL, Xie ZH, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by antiapoptotic protein Bcl-2. PNAS 1997;94:5113-8.
102. [102] Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997;277:370-2.
103. [103] Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
104. [104] Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of Caspase-3. Cell 1997;90:405-13.
105. [105] Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
106. [106] Kluck RM, Bossywetzel E, Green DR, Newmeyer DD. The release of cytochrome C from mitochondria - a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
107. [107] Yang J, Liu XS, Bhalla K, Kim CN, Ibrado AM, Cai JY, et al. Prevention of apoptosis by Bcl-2 - release of cytochrome C from mitochondria blocked. Science 1997;275:1129-32.
108. [108] White E. Life, death, and the pursuit of apoptosis. Gene Dev 1996;10:1-15.
109. [109] Hengartner MO. Death cycle and Swiss army knives. Nature 1998;391:441-2.
110. [110] Wallach D. Cell death induction by TNF: a matter of self control. Trends Biochem Sci 1997;22:107-9.
111. [111] Smith CA, Farrah T, Goodwill RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-62.
112. [112] Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 1997;385:729-33.
113. [113] Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-6.
114. [114] Tanaka M, Itai T, Adachi M, Shigekazu N. Downregulation of Fas ligand by shedding. Nature Med 1998;4:31-6.
115. [115] Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13.
116. [116] Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
117. [117] Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993;74:845-53.
118. [118] Itoh N, Nagata S. A novel protein domain required for apoptosis. J Biol Chem 1993;268:10932-7.
119. [119] Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-8.
120. [120] Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
121. [121] Hsu H, Xiong J, Goeddel DV. The TNF receptor I-associated protein TRADD signals cell death and NF-κB activation. Cell 1995;81:495-504.
122. [122] Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996;85:803-15.
123. [123] Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 1996;85:817-27.
124. [124] Irmler M, Thorne M, Hahne M, Schnider P, Hofmann K, Steiner V, et al. Inhihition of death receptor signals by cellular FLIP. Nature 1997;388:190-4.
125. [125] Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95-induced apoptosis. J Biol Chem 1997;272:17255-7.
126. [126] Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997;272:18542-5.
127. [127] Shu H-B, Halpin DR, Goeddel DV. Casper is a FADD-and Caspase-related inducer of apoptosis. Immunity 1997;6:751-63.
128. [128] Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D. CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997;272:19641-4.
129. [129] Inohara N, Koseki T, Hu Y, Chen S, Núñez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. PNAS 1997;94:10717-22.
130. [130] Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Sciden I, Keen SLC, et al. Cell death attentuation by 'Usurpin', a mammalian DED-caspasc homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 1998;5:271-88.
131. [131] Stanger BZ, Leder P, Lee T-H, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-23.
132. [132] Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature 1997;385:86-9.
133. [133] Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997;89:1067-76.
134. [134] Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95) -associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995;14:5579-88.
135. [135] Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krummer PH, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997;16:2794-804.
136. [136] Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995;14:6136-47.
137. [137] Chinnaiyan AM, Orth K, O'Rourke K, Duan H, Poirier GG, Dixit VM. Molecular ordering of the cell death pathway. J Biol Chem 1996;271:4573-6.
138. [138] Smith KGC, Strasser A, Vaux DL. CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmunedisease. EMBO J 1996;15:5167-76.
139. [139] Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of Fadd/Mort1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 1998;17:706-18.
140. [140] Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998;392:296-9.
141. [141] Yeh WC, Pompa JL, McCurrach ME, Shu HB, Elia AJ, Shahinian A, set al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-8.
142. [142] Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 blocks glucocorticoid-but not Fas-or activation-induced apoptosis in a T cell hybridoma. J Immunol 1995;115:4644-52.
143. [143] Lacronique V, Mignon A, Fahre M, Viollet B, Rouquet N, Molina T, et al. Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Med 1996;2:80-6.
144. [144] Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 1996;183:1031-6.
145. [145] Reference deleted in proof.
146. [146] Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-87.
147. [147] Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-50.
148. [148] Strasser A, O'Connor L. Fas ligand - caught between Scylla and Charybdis. Nature Med 1998;4:21-2.
149. [149] Yeh W-C, Shahinian A, Speiser D, Kraunus J, Billia F, Wakeham A, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997;7:715-25.
150. [150] Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 1997;7:703-13.
151. [151] Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 1998;8:297-303.
152. [152] Hsu H, Shu H-B, Pan M-G, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF Receptor 1 signal transduction pathways. Cell 1996;84:299-308.
153. [153] Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994;76:777-9.
154. [154] Tschopp J, Thome M, Hofmann K, Meinl E. The fight of viruses against apoptosis. Curr Opin Genet Dev 1998;8:82-7.
155. [155] Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Devel 1993;7:535-45.
156. [156] White E, Gooding LR. In: Tomei LD and Cope FO, editors. Apoptosis II: The Molecular Basis of Apoptosis in Disease. Cold Spring Harbor Laboratory Press, 1994:111-41.
157. [157] Ray CA, Black RA, Kronheim SR, Greenstreet GS, Pickup DJ. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992;69:597-604.
158. [158] Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. PNAS 1996;93:14486-91.
159. [159] Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, et al. Activation of interferon-γ inducing factor mediated by Interleukin-1β Converting Enzyme. Science 1997;275:206-9.
160. [160] Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995;375:81-3.
161. [161] Enari M, Hug H, Nagata S. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995;375:78-81.
162. [162] Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-7.
163. [163] Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, et al. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
164. [164] Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994;370:650-2.
165. [165] Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and Perforin show residual cytolylic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996;183:657-61.
166. [166] Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-53.
167. [167] Smith CA, Davis T, Wignall JM, Din WS, Farrah T, Upton C, et al. T2 open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem Biophys Res Commun 1991;176:335-42.
168. [168] Hu F-Q, Smith CA, Pickup DJ. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 1994;204:343-56.
169. [169] Gooding LR, Ranheim TS, Tollefson AE, Aquino L, Duerksen-Hughes P, Horton TM, et al. The 10,400-and 14,500-Dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol 1991;65:4114-23.
170. [170] Shisler J, Yang C, Walter B, Ware CF, Gooding LR. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 1997;71:8299-306.
171. [171] Bertin J, Armstrong RC, Ottilie S, Martin DS, Wang Y, Banks S, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis. PNAS 1996;94:1172-6.
172. [172]Thome M, Schneider P, Hofman K, Fickenscher H, Meinl E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386:517-21.
173. [173] Wang G-H, Bertin J, Wang Y, Martin DA, Wang J, Tomaselli KJ, Armstrong RC, Cohen JI. Bovine herpesvirus 4 BORFE2 protein inhibits Fas-and Tumor Necrosis Factor Receptor 1-induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses. J Virol 1997;71:8928-32.
174. [174] Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WSM. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 1988;53:341-6.
175. [175] Chen P, Tian J, Kovesdi I, Bruder JT. Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem 1998;273:5815-20.
176. [176] Ehrlich P, Morgenroth J. The collected papers of Paul Ehrlich. In: Himmelweit F, Marquardt HD. 1957:205-12.
177. [177] Nossal GJV. Negative selection of lymphocytes. Cell 1994;76:229-39.
178. [178] Tiwari JL, Terasaki PI. HLA and disease associations. New York, Springer-Verlag 1985.
179. [179] Ogawa M, Muruyama T, Hasegawa T. The inhibitory effect of neonatal thymectomy on the incidence of insulitis in non-obese-diabetic (NOD) mice. Biomed Res 1985;6:103-5.
180. [180] Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today 1989;10:104-7.
181. [181] Lindstrom J. Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model. Adv Immunol 1979;27:1-50.
182. [182] Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immonol Rev 1981;55:179-216.
183. [183] Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994;372:100-3.
184. [184] Lu L, Osmond DG. Apoptosis during B lymphopoiesis in mouse bone marrow. J Immunol 1997;158:5136-45.
185. [185] Egerton M, Scollay R, Shortman K. Kinetics of mature T cell development in the thymus. PNAS 1990;87:2579-82.
186. lo thymocytes in vivo. Science 1990;250:1720-3.
187. [187] Swat W, Ignatowicz L, von Boehmer H, Kisielow P. Clonal deletion of immature CD4+8+ thymocytes in suspension culture by extrathymic antigen-presenting cells. Nature 1991;351:150-3.
188. [188] Clayton LK, Ghendler Y, Mizoguchi E, Patch RJ, Ocain TD, Orth K, et al. T-cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: the molecular basis of negative selection. EMBO J 1997;16:2282-93.
189. [189] Akashi K, Kondo M, von Freeden-Jeffry U, Murray R, Weissman IL. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 1997;89:1033-41.
190. -l- mice. Cell 1997;89:1011-9.
191. [191] Kondo M, Akashi K, Domen J, Sugamura K, Weissman IL. Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common γ chain-deficient mice. Immunity 1997;7:155-62.
192. [192] Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X. Interleukin-2 receptor γ chain: a functional component of the interleukin-7 receptor. Science 1993;262:1877-80.
193. [193] Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S-I, et al. Functional participation of the IL-2 receptor γ chain in IL-7 receptor complexes. Science 1994;263:1453-4.
194. [194] Strasser A, Harris AW, Corcoran LM, Cory S. bcl-2 expression promotes B but not T lymphoid development in scid mice. Nature 1994;368:457-60.
195. + stage during positive selection and promotes thymocyte differentiation at several control points. Immunity 1994;1:197-205.
196. [196] Strasser A, Harris AW, Von Boehmer H, Cory S. Positive and negative selection of T cells in T cell receptor transgenic mice expressing a bcl-2 transgene. PNAS 1994;91:1376-80.
197. [197] Sidman CL, Marshall JD, von Boehmer H. Transgenic T cell receptor interactions in the lymphoproliferative and autoimmune syndromes of lpr and gld mutant mice. Eur J Immunol 1992;22:499-504.
198. [198] Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-71.
199. [199] Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simand JJL, Timms E, et al. Impaired negative selection of T cells in Hodgkin's Disease antigen CD30-deficient mice. Cell 1996;84:551-62.
200. [200] Tarlinton DM, Corcoran LM, Strasser A. Continued differentiation during B lymphopoiesis requires signals in addition to cell survival. Int Immunol 1997;9:1481-94.
201. [201] Young F, Mizoguchi E, Bhan AK, Alt FW. Constitutive Bcl-2 expression during immunoglobulin heavy chain-promoted B cell differentiation expands novel precursor B cells. Immunity 1997;6:23-33.
202. [202] Maraskovsky E, Peschon JJ, McKenna H, Teepe M, Strasser A. Overexpression of Bcl-2 does not rescue impaired B lymphopoiesis in interleukin-7 receptor-deficient mice but can enhance survival of mature B cells. Int Immunol; in press.
203. [203] Nisitani S, Tsubata T, Murakami M, Okamoto M, Honjo T. The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow. J Exp Med 1993;178:1247-54.
204. [204] Lang J, Arnold B, Hammerling G, Harris AW, Korsmeyer S, Russell D, et al. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. J Exp Med 1997;186:1513.-22
205. [205] Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72:325-35.
206. [206] Strasser A. Death of a T cell. Nature 1995;373:385-6.
207. [207] Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
208. [208] Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373:438-41.
209. [209] Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
210. [210] Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995;373:441-4.
211. [211] Van Parijs L, Biuckians A, Abbas AK. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 1998;160:2065-71.
212. [212] Van Parijs L, Peterson DA, Abbas AK. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998;8:265-74.
213. [213] McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991;349:254-6.
214. [214] Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. PNAS 1991;88:8661-5.
215. [215] Smith KGC, Weiss U, Rajewsky K, Nossal GJV, Tarlinton DM. BCL-2 increases memory B cell recruitment but does not perturb selection in germinal centers. Immunity 1994;1:808-13.
216. [216] O'Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J Immunol 1997;159:2301-11.
217. [217] Strasser A, Harris AW, Cory S. The role of bcl-2 in lymphoid differentiation and transformation. Curr Top Microbiol Immunol 1992;182:299-302.
218. [218] Rolink AG, Radaszkiewicz T, Melehers F. The autoantigen-binding B cell repertoires of normal and of chronically graft-versus-host-diseased mice. J Exp Med 1987;165:1675-87.
219. [219] Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferalion disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
220. [220] Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
221. [221] Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, et al. The mouse fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994;1:131-6.
222. [222] Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet 1995;11:294-300.
223. [223] Hahne M, Peitsch MC, Irmler M, Schröter M, Lowin B, Rousseau M, et al. Characterization of the non-functional Fas ligand of gld mice. Int Immunol 1995;7:1381-6.
224. [224] Izui S, Kelly VE, Masuda K, Yoshida H, Roths JB, Murphy ED. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 1984;133:227-33.
225. [225] Cohen PL, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today 1993;13:427-8.
226. [226] Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994;180:1295-306.
227. [227] Renno T, Hahne M, Tschopp J, MacDonald HR. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B200 and upregulate Fas and Fas ligand. J Exp Med 1996;183:431-7.
228. [228] Fukuyama H, Adachi M, Suematsu S, Miwa K, Suda T, Yoshida N, et al. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice. J Immunol 1998;160:3805-11.
229. [229] Nagata S. A death factor - the other side of the coin. Behring Inst Mitt 1996;97:1-11.
230. + T cells. Nature 1995;376:181-4.
231. [231] Rothstein TL, Wang JKM, Panka DJ, Foote LC, Wang Z, Stanger B, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995;374:163-5.
232. [232] Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediat 1967;70:891-9.
233. [233] Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
234. [234] Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
235. [235] Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferalive disorder. Int Immunol 1998;10:195-202.
236. [236] Dianzani U, Bragardo M, DiFranco D, Alliaudi C, Scagni P, Buonfiglio D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 1997;89:2871-9.
237. [237] Puck JM, Sneller MC. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Sem Immunol 1997;9:77-84.
238. [238] Sneller MC, Wang J, Dale JK, Strober W, Middleton LA, Choi Y, et al. Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89:1341-8.
239. [239] Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-9.
240. [240] Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
241. [241] Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-α. Clin Immunol Immunopathol 1996;81:293-302.
242. [242] Lorenz HM, Grünke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arth Rheum 1997;40:306-17.
243. [243] Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
244. [244] Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-7.
245. [245] Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995;38:1738-43.
246. [246] Mariani SM, Matiba B, Krammer PH. CD95 (APO-1/Fas) and its ligand in the mouse immune system. Behring Inst Mitt 1996;97:12-23.
247. [247] French LE, Tschopp J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt 1996;97:156-60.
248. [248] Nagata S. Fas ligand and immune evasion. Nature Med 1996;2:1306-7.
249. [249] Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
250. [250] Kotani T, Aratake Y, Hirai K, Fukazawa Y, Sato H, Ohtaki S. Apoptosis in thyroid tissue from patients with Hashimoto's thyroiditis. Autoimmunity 1995;20:231-6.
251. [251] Hammond LJ, Lowdell MW, Cerrano PG, Goode AW, Bottazzo GF, Mirakian R. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J Pathol 1997;182:138-44.
252. [252] Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275:960-3.
253. [253] Stokes TA, Rymaszewski M, Arscott PL, Wang SH, Bretz JD, Bartron J, et al. Constitutive expression of Fas ligand in thyrocytes. Science 1998;279:http://www.sciencemag.org/cgi/ content/full/279/5359/2015a.
254. [254] Fiedler P, Schaetzlein CE, Eibel H. Constitutive expression of Fas ligand in thyrocytes. Science 1998;279:http://www.sciencemag.org/cgi/content/full/279/5359/2015a.
255. [255] Smith D, Sieg S, Kaplan D. Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 1998;160:4159-60.
256. [256] Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA Jr., et al. The role of Fas in autoimmune diabetes. Cell 1997;89:17-24.
257. [257] Itoh N, Imagawa A, Hanafusa T, Wagura M, Yamamoto K, Iwahashi H, et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 1997;186:613-8.
258. [258] Watanabe D, Suda T, Hashimoto H, Nagata S. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBO J 1995;14:12-8.
259. [259] Kägi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997;186:989-97.
260. [260] Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-8.
261. [261] Oldstone MB. Viruses and autoimmune diseases. Scand J Immunol 1997;46:320-5.
262. [262] Notkins AL, Onodera T, Prabhakar B. In: Notkins AL and Oldstone MBA, editors. Concepts in viral pathogenesis. Heidelberg: Springer, 1984:210-5.
263. [263] von Herrath MG, Evans CF, Horwitz MS, Oldstone MB. Using transgenic mouse models to dissect the pathogenesis of virus-induced autoimmune disorders of the islets of Langerhans and the central nervous system. Immunol Rev 1996;152:111-43.
264. [264] Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response. Cell 1991;65:319-31.
265. [265] Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, et al. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-17.
266. [266] Rocken M, Urban JF, Shevach EM. Infection breaks T-cell tolerance. Nature 1992;359:79-82.
267. [267] Gamble DR, Taylor KW, Cumming H. Coxsackie viruses and diabetes mellitus. Br Med J 1973;4:260-2.
268. [268] Forrest JM, Menser MA, Burgess JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971;2:332-4.
269. [269] Lane DP, Hoeffler WK. SV40 large † shares an antigenic determinant with a cellular protein of molecular weight 68,000. Nature 1980;288:167-70.
270. [270] Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: cross-reaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci 1983;80:2346-50.
271. [271] Dales S, Fujinami RS, Oldstone MB. Infection with vaccinia favors the selection of hybridomas synthesizing autoantibodies against intermediate filaments, one of them cross-reacting with the virus hemagglutinin. J Immunol 1983;131:154653.
272. [272] Yoon J, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979;300:1173-9.
273. [273] Foulis AK, McGill M, Farquharson MA, Hilton DA. A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 1997;40:53-61.
274. [274] Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995;377:630-2.
275. [275] Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
276. [276] Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996;273:109-12.
277. [277] Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts. PNAS 1997;94:3943-7.
278. [278] Kang S-M, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 1997;3:738-43.